| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
EGGGG‑PEG8‑amide‑bis(deoxyglucitol) has no direct biological target. As an ADC linker, it serves as a cleavable bridge to connect antibodies to cytotoxic payloads. The EGGGG peptide sequence may be designed for protease‑mediated cleavage (e.g., by cathepsins), while the PEG8 spacer enhances hydrophilicity and reduces aggregation. The deoxyglucitol sugar groups further improve water solubility and may reduce non‑specific interactions.
|
|---|---|
| ln Vitro |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is a synthetic building block with no intrinsic biological activity. Its utility is evaluated through the performance of complete ADCs incorporating it. In vitro, ADCs built with this linker are expected to show potent, target‑dependent killing of cancer cells and reduced non‑specific binding due to the hydrophilic PEG and sugar moieties.
|
| ln Vivo |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is not administered in vivo as a standalone compound. ADCs constructed with this linker are expected to demonstrate improved pharmacokinetics, reduced liver uptake, and enhanced tumor penetration due to the highly hydrophilic nature of the linker, but formal in vivo efficacy data for a specific ADC using this exact linker have not been published.
|
| Enzyme Assay |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is not used in direct enzyme/receptor binding assays. The cleavability of the peptide sequence in the linker can be evaluated using a model fluorogenic substrate approach: a peptide‑containing compound with a fluorophore‑quencher pair is synthesized, and fluorescence increase upon incubation with lysosomal proteases (e.g., cathepsin B) is measured, but this is not a standard protocol for this specific linker.
|
| Cell Assay |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is not tested directly on cells. Functional validation of an ADC incorporating this linker involves treating target antigen‑positive cancer cells with the ADC (0.001-100 nM) for 72-96 h. Cell viability is assessed by CellTiter‑Glo. The highly hydrophilic linker design is intended to minimize non‑specific uptake and reduce cytotoxicity in antigen‑negative cells.
|
| Animal Protocol |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) alone is not evaluated in animals. ADCs using this linker (e.g., conjugated to a cytotoxic payload and a tumor‑targeting antibody) are expected to be tested in mouse xenograft models. The PEG8 and deoxyglucitol groups are intended to prolong circulation time, reduce immunogenicity, and enhance tumor accumulation. Endpoints would include tumor volume inhibition and body weight monitoring.
|
| ADME/Pharmacokinetics |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is a chemical linker not intended for standalone administration. For ADCs constructed with this linker, the highly hydrophilic PEG8 and sugar groups are expected to reduce aggregation, increase solubility, and decrease clearance by the reticuloendothelial system (RES), potentially extending the ADC's circulation half‑life compared to more hydrophobic linkers.
|
| Toxicity/Toxicokinetics |
Not applicable; EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is not a drug substance and is not tested in standalone toxicology studies. The hydrophilic nature of this linker is intended to reduce off‑target toxicity and immunogenicity of the final ADC. No specific toxicity data are available for this linker alone.
|
| Additional Infomation |
EGGGG‑PEG8‑amide‑bis(deoxyglucitol) is a research‑grade chemical reagent for the custom synthesis of ADCs. It is not a therapeutic agent and has not been approved for human use. The combination of a PEG8 spacer, a glycine‑rich peptide, and deoxyglucitol sugar groups is a specialized design to improve ADC solubility and biocompatibility, making it valuable for developing next‑generation ADCs with improved pharmacokinetic profiles.
|
| Molecular Formula |
C49H91N9O28
|
|---|---|
| Molecular Weight |
1254.29
|
| Exact Mass |
1253.597
|
| CAS # |
2842855-38-1
|
| PubChem CID |
168510643
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
20
|
| Rotatable Bond Count |
56
|
| Heavy Atom Count |
86
|
| Complexity |
1900
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C(CC(=O)O)[C@@H](C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)C(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)N
|
| InChi Key |
SRJGEXWUUWWJCQ-OJWWGKDHSA-N
|
| InChi Code |
InChI=1S/C49H91N9O28/c50-31(1-4-43(71)72)48(77)57-28-42(70)55-27-41(69)54-26-40(68)53-25-39(67)51-6-8-80-10-12-82-14-16-84-18-20-86-22-21-85-19-17-83-15-13-81-11-9-79-7-5-38(66)58-32(49(78)56-24-34(62)45(74)47(76)36(64)30-60)2-3-37(65)52-23-33(61)44(73)46(75)35(63)29-59/h31-36,44-47,59-64,73-76H,1-30,50H2,(H,51,67)(H,52,65)(H,53,68)(H,54,69)(H,55,70)(H,56,78)(H,57,77)(H,58,66)(H,71,72)/t31-,32-,33-,34-,35+,36+,44+,45+,46+,47+/m0/s1
|
| Chemical Name |
(4S)-4-amino-5-[[2-[[2-[[2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1,5-dioxo-1,5-bis[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 75 mg/mL (59.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7973 mL | 3.9863 mL | 7.9726 mL | |
| 5 mM | 0.1595 mL | 0.7973 mL | 1.5945 mL | |
| 10 mM | 0.0797 mL | 0.3986 mL | 0.7973 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
